Beijing Danxu Biopharmaceuticals

Danxu Biopharma is a clinical-stage biotechnology company headquartered in Beijing, China, focused on the discovery and development of next-generation antibody therapies. The company utilizes a proprietary high-throughput single-cell sequencing platform to rapidly identify potent neutralizing antibodies from convalescent patients. Danxu rose to international attention for its rapid response to the COVID-19 pandemic, advancing candidates like DXP-593 and DXP-604 into clinical trials. Its technology platform, developed in collaboration with Peking University, allows for the screening of thousands of antibody-producing cells in a fraction of the time required by traditional methods. While infectious diseases remain a core focus, the company is also leveraging its discovery engine to develop treatments for oncology and autoimmune disorders. Danxu is supported by a strong syndicate of investors, including Hillhouse Capital and Qiming Venture Partners, to accelerate its pipeline development.